Cassava Sciences (SAVA) Competitors $2.12 +0.07 (+3.41%) Closing price 04:00 PM EasternExtended Trading$2.12 0.00 (0.00%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA vs. CKPT, SNDL, TRDA, OLMA, HRTX, ARCT, SEPN, BNTC, FULC, and ATYRShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Checkpoint Therapeutics (CKPT), SNDL (SNDL), Entrada Therapeutics (TRDA), Olema Pharmaceuticals (OLMA), Heron Therapeutics (HRTX), Arcturus Therapeutics (ARCT), Septerna (SEPN), Benitec Biopharma (BNTC), Fulcrum Therapeutics (FULC), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. Cassava Sciences vs. Checkpoint Therapeutics SNDL Entrada Therapeutics Olema Pharmaceuticals Heron Therapeutics Arcturus Therapeutics Septerna Benitec Biopharma Fulcrum Therapeutics Atyr PHARMA Checkpoint Therapeutics (NASDAQ:CKPT) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk. Does the media refer more to CKPT or SAVA? In the previous week, Checkpoint Therapeutics and Checkpoint Therapeutics both had 1 articles in the media. Checkpoint Therapeutics' average media sentiment score of 0.56 beat Cassava Sciences' score of 0.18 indicating that Checkpoint Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Checkpoint Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate CKPT or SAVA? Checkpoint Therapeutics presently has a consensus target price of $4.33, indicating a potential upside of 3.54%. Cassava Sciences has a consensus target price of $54.50, indicating a potential upside of 2,489.07%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community favor CKPT or SAVA? Checkpoint Therapeutics received 84 more outperform votes than Cassava Sciences when rated by MarketBeat users. Likewise, 67.16% of users gave Checkpoint Therapeutics an outperform vote while only 64.47% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformCheckpoint TherapeuticsOutperform Votes18267.16% Underperform Votes8932.84% Cassava SciencesOutperform Votes9864.47% Underperform Votes5435.53% Which has higher earnings and valuation, CKPT or SAVA? Checkpoint Therapeutics has higher revenue and earnings than Cassava Sciences. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheckpoint Therapeutics$41K8,550.06-$51.85M-$1.29-3.24Cassava SciencesN/AN/A-$97.22M-$1.50-1.40 Is CKPT or SAVA more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Checkpoint TherapeuticsN/A N/A -659.07% Cassava Sciences N/A -88.05%-64.98% Which has more risk & volatility, CKPT or SAVA? Checkpoint Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -2.31, meaning that its share price is 331% less volatile than the S&P 500. Do insiders and institutionals have more ownership in CKPT or SAVA? 22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by company insiders. Comparatively, 2.4% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryCheckpoint Therapeutics beats Cassava Sciences on 8 of the 14 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.65M$6.49B$5.33B$8.43BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-1.549.1226.8519.75Price / SalesN/A256.15388.74118.67Price / CashN/A65.8538.2534.62Price / Book0.656.436.764.50Net Income-$97.22M$144.21M$3.23B$248.32M7 Day Performance2.68%2.25%1.71%0.48%1 Month Performance32.39%4.39%11.16%13.08%1 Year Performance-90.48%-2.71%17.17%7.36% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences3.8109 of 5 stars$2.12+3.4%$54.50+2,470.8%-90.8%$102.41MN/A-1.5430CKPTCheckpoint Therapeutics2.2261 of 5 stars$4.17-0.1%$4.33+4.0%+110.1%$348.88M$41,000.00-2.2610News CoverageNegative NewsSNDLSNDL3.0714 of 5 stars$1.32+2.3%$3.63+174.6%-44.5%$346.86M$927.61M-4.26580Positive NewsTRDAEntrada Therapeutics3.119 of 5 stars$8.83+5.4%$25.67+190.5%-51.0%$335.28M$172.22M5.56110News CoverageAnalyst ForecastAnalyst RevisionOLMAOlema Pharmaceuticals2.2672 of 5 stars$4.76+3.6%$27.67+480.7%-46.5%$325.67MN/A-2.1870Positive NewsGap UpHRTXHeron Therapeutics3.8232 of 5 stars$2.07-2.1%$5.50+166.3%-45.3%$315.05M$148.52M-11.47300Positive NewsAnalyst DowngradeARCTArcturus Therapeutics2.9262 of 5 stars$11.56+5.3%$59.20+412.2%-59.3%$313.44M$138.39M-5.21180Analyst UpgradeSEPNSepterna2.0734 of 5 stars$6.99+4.4%$33.00+372.4%N/A$310.94M$1.08M0.00N/AEarnings ReportAnalyst RevisionBNTCBenitec Biopharma2.2432 of 5 stars$13.26-2.8%$24.71+86.5%+42.3%$310.84M$80,000.00-8.7820News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap UpFULCFulcrum Therapeutics0.7972 of 5 stars$5.67+5.6%$8.63+52.1%-18.2%$306.06M$80M-18.29100ATYRAtyr PHARMA2.8226 of 5 stars$3.25-1.1%$18.60+473.2%N/A$288.82M$235,000.00-3.4553Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Checkpoint Therapeutics Competitors SNDL Competitors Entrada Therapeutics Competitors Olema Pharmaceuticals Competitors Heron Therapeutics Competitors Arcturus Therapeutics Competitors Septerna Competitors Benitec Biopharma Competitors Fulcrum Therapeutics Competitors Atyr PHARMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAVA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SAVA Stock Free SAVA Stock Alerts